SACUSMART 200: Sacubitril and Valsartan Tablets for Chronic Heart Failure Management

 SACUSMART 200, manufactured by Steris Healthcare, is a fixed-dose combination of Sacubitril 97 mg and Valsartan 103 mg, belonging to a class of drugs known as Angiotensin Receptor-Neprilysin Inhibitors (ARNI). It is prescribed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) in adults, to reduce the risk of cardiovascular death and heart failure-related hospitalization. It is typically used in place of an ACE inhibitor or ARB once a patient is stabilized, as part of a broader heart failure management regimen alongside beta-blockers, diuretics, and other guideline-directed therapies. SACUSMART 200 represents one of the more significant advances in heart failure pharmacotherapy in recent decades, offering benefits beyond traditional single-mechanism drugs.

Why It's Important

Chronic heart failure is a progressive condition with high rates of hospitalization and mortality if inadequately managed. Traditional therapies targeting the renin-angiotensin system alone often leave residual risk unaddressed. SACUSMART 200's dual mechanism — combining neprilysin inhibition with angiotensin receptor blockade — has been shown in major clinical trials to significantly reduce cardiovascular death and hospitalization compared to ACE inhibitor therapy alone. For patients living with heart failure, this translates into fewer hospital admissions, improved exercise tolerance, and a meaningfully better quality of life, making early initiation and consistent adherence clinically important rather than optional.

Key Benefits 

What are the benefits?

• Reduces risk of cardiovascular death in heart failure patients
• Lowers hospitalization rates due to worsening heart failure
• Improves symptoms such as breathlessness and fatigue over time
• Supports better exercise tolerance and functional capacity
• Dual-action mechanism offers benefits beyond standard ACE inhibitor/ARB therapy
• Manufactured under WHO-GMP and ISO 9001:2018 certified facility standards by Steris Healthcare, ensuring consistent quality and reliability

Side Effects

Common side effects may include dizziness, low blood pressure (hypotension), elevated potassium levels (hyperkalemia), cough, and mild fatigue. These are usually manageable with dose adjustment and monitoring by a physician.

Serious Side Effects 

Patients should seek urgent medical attention for symptoms of angioedema (swelling of the face, lips, tongue, or throat with difficulty breathing), signs of severe kidney impairment (reduced urination, swelling), persistent low blood pressure with fainting, or symptoms of severe hyperkalemia such as muscle weakness or irregular heartbeat. These require immediate clinical evaluation.

Available Substitute 

Multiple branded formulations of Sacubitril and Valsartan combination tablets are available in the Indian pharmaceutical market at equivalent strengths. Switching between brands should only be done under physician supervision, as this is a critical cardiac medication where consistency in bioavailability and quality directly impacts therapeutic outcomes.

Dosage Guidelines 

Dosage is individualized by the treating cardiologist based on prior ACE inhibitor/ARB use, blood pressure, and renal function, typically starting at a lower strength and titrated upward every 2–4 weeks as tolerated. It is usually taken twice daily, with or without food, at consistent times to maintain stable drug levels. A washout period of at least 36 hours is required when switching from an ACE inhibitor to avoid angioedema risk. Missed doses should be taken as soon as remembered unless close to the next scheduled dose.

Precautions & Warnings

SACUSMART 200 must not be used concomitantly with ACE inhibitors due to the risk of life-threatening angioedema, and should not be combined with other ARBs. It is contraindicated in patients with a history of angioedema related to prior ACE inhibitor or ARB therapy, and in pregnancy due to risk of fetal harm. Caution is required in patients with renal impairment, hepatic impairment, or those on potassium-sparing diuretics or potassium supplements. Regular monitoring of blood pressure, renal function, and serum potassium is recommended throughout therapy.

Mechanism of Action

SACUSMART 200 works through a dual and complementary mechanism. Sacubitril, via its active metabolite, inhibits neprilysin — an enzyme responsible for breaking down natriuretic peptides, bradykinin, and other vasoactive substances. This inhibition increases levels of natriuretic peptides, promoting vasodilation, natriuresis (sodium excretion), and reduced cardiac remodeling. Simultaneously, Valsartan blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction, aldosterone release, and sympathetic activation driven by the renin-angiotensin-aldosterone system. Together, this combination reduces the workload on the failing heart while counteracting the maladaptive neurohormonal responses that drive heart failure progression.

Conclusion

SACUSMART 200 by Steris Healthcare offers a clinically advanced, evidence-based approach to managing chronic heart failure with reduced ejection fraction, addressing both neurohormonal overactivation and inadequate natriuretic peptide activity. Its proven reduction in cardiovascular mortality and hospitalization makes it a cornerstone therapy in modern heart failure management. As with all cardiac medications, initiation, titration, and monitoring should be strictly guided by a qualified cardiologist.